

Peter C Gätzsche

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3405173/publications.pdf>

Version: 2024-02-01

140
papers

70,777
citations

31976

53
h-index

10445

139
g-index

157
all docs

157
docs citations

157
times ranked

87844
citing authors

#	ARTICLE	IF	CITATIONS
1	EMA's mishandling of an investigation into suspected serious neurological harms of HPV vaccines. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 7-10.	3.5	3
2	Restoring the two pivotal fluoxetine trials in children and adolescents with depression. <i>International Journal of Risk and Safety in Medicine</i> , 2022, , 1-24.	0.6	1
3	House dust mite control measures for asthma. <i>The Cochrane Library</i> , 2021, 2021, CD001187.	2.8	137
4	Cochrane authors on drug industry payroll should not be allowed. <i>BMJ Evidence-Based Medicine</i> , 2020, 25, 120-121.	3.5	2
5	The coronavirus pandemic: can we handle such epidemics better?. <i>Journal of the Royal Society of Medicine</i> , 2020, 113, 171-175.	2.0	3
6	Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports. <i>Systematic Reviews</i> , 2020, 9, 43.	5.3	12
7	Presentation of benefits and harms of antidepressants on websites: A cross-sectional study. <i>International Journal of Risk and Safety in Medicine</i> , 2020, 31, 53-65.	0.6	12
8	What have antidepressants been tested for? A systematic review. <i>International Journal of Risk and Safety in Medicine</i> , 2020, 31, 157-163.	0.6	3
9	Drop-out rates in placebo-controlled trials of antidepressant drugs: A systematic review and meta-analysis based on clinical study reports. <i>International Journal of Risk and Safety in Medicine</i> , 2019, 30, 217-232.	0.6	9
10	Institute for Scientific Freedom. <i>BMJ Evidence-Based Medicine</i> , 2019, 24, 123-124.	3.5	0
11	Do protocols for new randomised trials take previous similar trials into account? Cohort study of contemporary trial protocols. <i>BMJ Open</i> , 2019, 9, e026661.	1.9	8
12	Screening for reducing morbidity and mortality in malignant melanoma. <i>The Cochrane Library</i> , 2019, 2019, CD012352.	2.8	37
13	Redactions in protocols for drug trials: what industry sponsors concealed. <i>Journal of the Royal Society of Medicine</i> , 2018, 111, 136-141.	2.0	12
14	A totally new system is needed for drug research and development. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12883.	3.4	5
15	Patients not patents: Drug research and development as a public enterprise. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12875.	3.4	9
16	Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors. <i>BMJ: British Medical Journal</i> , 2018, 363, k3654.	2.3	42
17	Challenges of independent assessment of potential harms of HPV vaccines. <i>BMJ: British Medical Journal</i> , 2018, 362, k3694.	2.3	13
18	Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review. <i>Systematic Reviews</i> , 2018, 7, 8.	5.3	21

#	ARTICLE	IF	CITATIONS
19	Breast Cancer Screening in Denmark. <i>Annals of Internal Medicine</i> , 2017, 166, 313.	3.9	102
20	Psychopharmacology Is Not Evidence-Based Medicine. , 2017, , 23-49.		1
21	Cognitive behavioural therapy halves the risk of repeated suicide attempts: systematic review. <i>Journal of the Royal Society of Medicine</i> , 2017, 110, 404-410.	2.0	55
22	The Yusuf-Peto method was not a robust method for meta-analyses of rare events data from antidepressant trials. <i>Journal of Clinical Epidemiology</i> , 2017, 91, 129-136.	5.0	15
23	Impaired reproduction after exposure to ADHD drugs: Systematic review of animal studies. <i>International Journal of Risk and Safety in Medicine</i> , 2017, 29, 107-124.	0.6	6
24	Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. <i>The Cochrane Library</i> , 2016, 2016, CD007851.	2.8	51
25	Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers. <i>Journal of the Royal Society of Medicine</i> , 2016, 109, 381-392.	2.0	43
26	“Adaptive pathways” to drug authorisation: adapting to industry?. <i>BMJ, The</i> , 2016, 354, i4437.	6.0	38
27	Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. <i>BMJ, The</i> , 2016, 352, i65.	6.0	228
28	Updated screening guidelines “much ado about small improvements. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 139-140.	27.6	5
29	Screening with urinary dipsticks for reducing morbidity and mortality. <i>The Cochrane Library</i> , 2015, 2015, CD010007.	2.8	16
30	Does long term use of psychiatric drugs cause more harm than good?. <i>BMJ, The</i> , 2015, 350, h2435-h2435.	6.0	64
31	Author's reply to Tovey and colleagues. <i>BMJ, The</i> , 2015, 350, h2955-h2955.	6.0	1
32	Mammography screening is harmful and should be abandoned. <i>Journal of the Royal Society of Medicine</i> , 2015, 108, 341-345.	2.0	33
33	SPIRIT 2013 Statement: defining standard protocol items for clinical trials. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2015, 38, 506-14.	1.1	114
34	Comparison of Results from Different Imputation Techniques for Missing Data from an Anti-Obesity Drug Trial. <i>PLoS ONE</i> , 2014, 9, e111964.	2.5	30
35	"Human guinea pig" asks for animal studies. <i>BMJ, The</i> , 2014, 349, g6714-g6714.	6.0	7
36	Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study. <i>BMJ, The</i> , 2014, 348, g3555-g3555.	6.0	11

#	ARTICLE	IF	CITATIONS
37	Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. <i>BMJ, The</i> , 2014, 348, g3510-g3510.	6.0	56
38	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. <i>International Journal of Surgery</i> , 2014, 12, 1500-1524.	2.7	1,698
39	Study of study of changes in antidepressant use after FDA warnings is not reliable. <i>BMJ, The</i> , 2014, 349, g5623-g5623.	6.0	1
40	General health checks don't work. <i>BMJ, The</i> , 2014, 348, g3680-g3680.	6.0	32
41	Muscular adverse effects are common with statins. <i>BMJ, The</i> , 2014, 348, g3724-g3724.	6.0	3
42	Increasing value and reducing waste: addressing inaccessible research. <i>Lancet, The</i> , 2014, 383, 257-266.	13.7	692
43	Lead-Time Models Produce Far Too Low Estimates of Overdiagnosis With Mammographic Screening. <i>Journal of the American College of Radiology</i> , 2014, 11, 1098.	1.8	3
44	Why I think antidepressants cause more harm than good. <i>Lancet Psychiatry, the</i> , 2014, 1, 104-106.	7.4	32
45	Lead-Time Models Should Not Be Used to Estimate Overdiagnosis in Cancer Screening. <i>Journal of General Internal Medicine</i> , 2014, 29, 1283-1286.	2.6	32
46	Strategies for obtaining unpublished drug trial data: a qualitative interview study. <i>Systematic Reviews</i> , 2013, 2, 31.	5.3	22
47	Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study. <i>BMC Medical Ethics</i> , 2013, 14, 19.	2.4	78
48	Screening for breast cancer with mammography. <i>The Cochrane Library</i> , 2013, 2013, CD001877.	2.8	814
49	Citations of scientific results and conflicts of interest: the case of mammography screening. <i>Evidence-Based Medicine</i> , 2013, 18, 83-89.	0.6	19
50	SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. <i>BMJ, The</i> , 2013, 346, e7586-e7586.	6.0	3,435
51	SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. <i>Annals of Internal Medicine</i> , 2013, 158, 200.	3.9	4,463
52	Strengthening and Opening Up Health Research by Sharing Our Raw Data. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 236-237.	2.2	28
53	The Two-County Breast Screening Trial Cannot Provide a Reliable Estimate of the Effect of Breast Cancer Screening. <i>Radiology</i> , 2012, 262, 729-730.	7.3	2
54	Content area experts as authors: helpful or harmful for systematic reviews and meta-analyses?. <i>BMJ, The</i> , 2012, 345, e7031-e7031.	6.0	73

#	ARTICLE	IF	CITATIONS
55	Deficiencies in proposed new EU regulation of clinical trials. <i>BMJ, The</i> , 2012, 345, e8522-e8522.	6.0	16
56	Mammography screening: truth, lies, and controversy. <i>Lancet, The</i> , 2012, 380, 218.	13.7	32
57	Big pharma often commits corporate crime, and this must be stopped. <i>BMJ, The</i> , 2012, 345, e8462-e8462.	6.0	16
58	CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. <i>International Journal of Surgery</i> , 2012, 10, 28-55.	2.7	1,546
59	Sponsors'™ participation in conduct and reporting of industry trials: a descriptive study. <i>Trials</i> , 2012, 13, 146.	1.6	46
60	What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin reuptake inhibitors. <i>Addiction</i> , 2012, 107, 900-908.	3.3	85
61	Why mammography screening has not lived up to expectations from the randomised trials. <i>Cancer Causes and Control</i> , 2012, 23, 15-21.	1.8	60
62	Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. <i>Lancet Oncology, The</i> , 2011, 12, 1118-1124.	10.7	83
63	Access to data in industry-sponsored trials. <i>Lancet, The</i> , 2011, 378, 1995-1996.	13.7	25
64	Why we need easy access to all data from all clinical trials and how to accomplish it. <i>Trials</i> , 2011, 12, 249.	1.6	114
65	Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. <i>BMC Medical Research Methodology</i> , 2011, 11, 22.	3.1	136
66	Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. <i>BMJ: British Medical Journal</i> , 2011, 343, d4692-d4692.	2.3	45
67	Is Mammographic Screening Justifiable Considering Its Substantial Overdiagnosis Rate and Minor Effect on Mortality?. <i>Radiology</i> , 2011, 260, 621-627.	7.3	114
68	Opening up data at the European Medicines Agency. <i>BMJ: British Medical Journal</i> , 2011, 342, d2686-d2686.	2.3	94
69	The Breast Screening Programme and misinforming the public. <i>Journal of the Royal Society of Medicine</i> , 2011, 104, 361-369.	2.0	36
70	Screening for breast cancer with mammography. , 2011, , CD001877.		209
71	Time to stop mammography screening?. <i>Cmaj</i> , 2011, 183, 1957-1958.	2.0	37
72	Relation between breast cancer mortality and screening effectiveness: systematic review of the mammography trials. <i>Danish Medical Bulletin</i> , 2011, 58, A4246.	0.3	8

#	ARTICLE	IF	CITATIONS
73	Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. BMJ: British Medical Journal, 2010, 341, c3920-c3920.	2.3	280
74	CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ: British Medical Journal, 2010, 340, c869-c869.	2.3	5,319
75	Adequacy of authors' replies to criticism raised in electronic letters to the editor: cohort study. BMJ: British Medical Journal, 2010, 341, c3926-c3926.	2.3	25
76	Unbalanced reporting of benefits and harms in abstracts on rofecoxib. European Journal of Clinical Pharmacology, 2010, 66, 341-347.	1.9	4
77	Breast screening: why estimates differ by a factor of 20-25. Journal of Medical Screening, 2010, 17, 158-159.	2.3	8
78	Who evaluates public health programmes? A review of the NHS Breast Screening Programme. Journal of the Royal Society of Medicine, 2010, 103, 14-20.	2.0	17
79	Breast cancer mortality in organised mammography screening in Denmark: comparative study. BMJ: British Medical Journal, 2010, 340, c1241-c1241.	2.3	165
80	Sleep apnoea: from person to patient, and back again. BMJ: British Medical Journal, 2010, 340, c360-c360.	2.3	1
81	CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. Journal of Clinical Epidemiology, 2010, 63, e1-e37.	5.0	1,500
82	Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. , 2010, , CD007851.		39
83	Intravenous alpha-1 antitrypsin augmentation therapy: systematic review. Danish Medical Bulletin, 2010, 57, A4175.	0.3	4
84	What Should Be Done To Tackle Ghostwriting in the Medical Literature?. PLoS Medicine, 2009, 6, e1000023.	8.4	91
85	Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ: British Medical Journal, 2009, 339, b2587-b2587.	2.3	407
86	The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ: British Medical Journal, 2009, 339, b2700-b2700.	2.3	13,452
87	Screening for breast cancer with mammography. , 2009, , CD001877.		152
88	The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. PLoS Medicine, 2009, 6, e1000100.	8.4	13,772
89	Overdiagnosis in organised mammography screening in Denmark. A comparative study. BMC Women's Health, 2009, 9, 36.	2.0	80
90	Readers as research detectives. Trials, 2009, 10, 2.	1.6	8

#	ARTICLE	IF	CITATIONS
91	The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. <i>Journal of Clinical Epidemiology</i> , 2009, 62, e1-e34.	5.0	8,425
92	Disagreements in meta-analyses using outcomes measured on continuous or rating scales: observer agreement study. <i>BMJ: British Medical Journal</i> , 2009, 339, b3128-b3128.	2.3	59
93	Breast screening: the facts—or maybe not. <i>BMJ: British Medical Journal</i> , 2009, 338, b86-b86.	2.3	128
94	Covert duplicate publication and misleading sample size calculation: Commentary on Lee et al. (2008). <i>International Journal of Nursing Studies</i> , 2008, 45, 1398.	5.6	2
95	Somatostatin analogues for acute bleeding oesophageal varices. <i>The Cochrane Library</i> , 2008, , CD000193.	2.8	61
96	Biases in estimates of over-detection due to mammography screening. <i>Lancet Oncology</i> , The, 2008, 9, 199-201.	10.7	15
97	Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. <i>BMJ: British Medical Journal</i> , 2008, 337, a2299-a2299.	2.3	161
98	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. <i>PLoS Medicine</i> , 2007, 4, e297.	8.4	3,710
99	Ghost Authorship in Industry-Initiated Randomised Trials. <i>PLoS Medicine</i> , 2007, 4, e19.	8.4	220
100	Data Extraction Errors in Meta-analyses That Use Standardized Mean Differences. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 430-7.	7.4	158
101	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). <i>Epidemiology</i> , 2007, 18, 805-835.	2.7	1,717
102	Mammographic screening from age 40 years. <i>Lancet</i> , The, 2007, 369, 737-738.	13.7	2
103	Undeclared motives in withdrawing a publication. <i>Lancet</i> , The, 2007, 369, 1690.	13.7	0
104	Asthma guidelines on house dust mites are not evidence-based. <i>Lancet</i> , The, 2007, 370, 2100-2101.	13.7	7
105	Are benefits and harms in mammography screening given equal attention in scientific articles? A cross-sectional study. <i>BMC Medicine</i> , 2007, 5, 12.	5.5	42
106	What is publication?. <i>Lancet</i> , The, 2006, 368, 1854-1856.	13.7	5
107	Believability of relative risks and odds ratios in abstracts: cross sectional study. <i>BMJ: British Medical Journal</i> , 2006, 333, 231-234.	2.3	72
108	Unsubstantiated claims of large effects of placebo on pain: serious errors in meta-analysis of placebo analgesia mechanism studies. <i>Journal of Clinical Epidemiology</i> , 2006, 59, 336-338.	5.0	40

#	ARTICLE	IF	CITATIONS
109	Content of invitations for publicly funded screening mammography. <i>BMJ: British Medical Journal</i> , 2006, 332, 538-541.	2.3	121
110	Screening for breast cancer with mammography. , 2006, , CD001877.		198
111	Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations. <i>Trials</i> , 2006, 7, 3.	1.6	12
112	Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. <i>International Journal of Cancer</i> , 2006, 118, 2648-2648.	5.1	2
113	Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. <i>BMJ: British Medical Journal</i> , 2006, 333, 782.	2.3	366
114	Constraints on Publication Rights in Industry-Initiated Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1641.	7.4	66
115	Lessons From and Cautions About Noninferiority and Equivalence Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1172.	7.4	88
116	Results of the Two-County trial of mammography screening are not compatible with contemporaneous official Swedish breast cancer statistics. <i>European Journal of Cancer</i> , 2006, , .	2.8	5
117	Results of the Two-County trial of mammography screening are not compatible with contemporaneous official Swedish breast cancer statistics. <i>Danish Medical Bulletin</i> , 2006, 53, 438-40.	0.3	4
118	Empirical Evidence for Selective Reporting of Outcomes in Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 2457.	7.4	1,509
119	Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study. <i>BMJ: British Medical Journal</i> , 2004, 328, 148-0.	2.3	122
120	On the benefits and harms of screening for breast cancer. <i>International Journal of Epidemiology</i> , 2004, 33, 56-64.	1.9	42
121	The debate on breast cancer screening with mammography is important. <i>Journal of the American College of Radiology</i> , 2004, 1, 8-14.	1.8	9
122	Mammography service screening and mortality. <i>Lancet, The</i> , 2003, 362, 329-330.	13.7	6
123	Are encasings effective in asthma caused by house dust mite allergens?. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 220.	2.9	6
124	Regular self-examination or clinical examination for early detection of breast cancer. <i>The Cochrane Library</i> , 2003, , CD003373.	2.8	198
125	Prevalence of Honorary and Ghost Authorship in Cochrane Reviews. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 2769.	7.4	186
126	Screening mammography: setting the record straight. <i>Lancet, The</i> , 2002, 359, 440-441.	13.7	4

#	ARTICLE	IF	CITATIONS
127	Update on effects of screening mammography. Lancet, The, 2002, 360, 338-339.	13.7	7
128	Trends in breast-conserving surgery in the Southeast Netherlands. European Journal of Cancer, 2002, 38, 1288.	2.8	8
129	Invited response. Journal of Surgical Oncology, 2002, 81, 162-163.	1.7	2
130	Beyond randomized controlled trials. Cancer, 2002, 94, 578-578.	4.1	6
131	Cochrane review on screening for breast cancer with mammography. Lancet, The, 2001, 358, 1340-1342.	13.7	661
132	Screening for breast cancer with mammography. Lancet, The, 2001, 358, 2167-2168.	13.7	28
133	Screening mammography re-evaluated. Lancet, The, 2000, 355, 752.	13.7	13
134	More on mammography. Lancet, The, 2000, 356, 1276.	13.7	2
135	Is screening for breast cancer with mammography justifiable?. Lancet, The, 2000, 355, 129-134.	13.7	803
136	Somatostatin for acute oesophageal variceal bleeding. Lancet, The, 1998, 351, 911.	13.7	2
137	House dust mite control measures in the management of asthma: meta-analysis. BMJ: British Medical Journal, 1998, 317, 1105-1110.	2.3	185
138	Beware of Surrogate Outcome Measures. International Journal of Technology Assessment in Health Care, 1996, 12, 238-246.	0.5	94
139	Blinding during data analysis and writing of manuscripts. Contemporary Clinical Trials, 1996, 17, 285-290.	1.9	108
140	Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Contemporary Clinical Trials, 1989, 10, 31-56.	1.9	295